Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 3Neoplasms 2Lymphatic Metastasis 2Thyroid Nodule 1Social Isolation 1Rectal Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Ovarian Neoplasms 1Neurobehavioral Manifestations 1Lung Neoplasms 1Disease 1Depression 1Communication 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Anxiety Disorders 1

Interventions

Fulvestrant 125Trastuzumab 114Paclitaxel 113Letrozole 108pembrolizumab 79pertuzumab 75palbociclib 75Capecitabine 72Anastrozole 72Cyclophosphamide 70Carboplatin 67abemaciclib 64exemestane 63Tamoxifen 63ribociclib 60trastuzumab deruxtecan 57Surveys and Questionnaires 51Specimen Handling 50Radiotherapy 49Docetaxel 49Magnetic Resonance Spectroscopy 48Blood Specimen Collection 40olaparib 39Standard of Care 36Biopsy 33sacituzumab govitecan 31130-nm albumin-bound paclitaxel 31Doxorubicin 30Exercise 29eribulin 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Artificial Intelligence × 1 year × Clear all
NCT04340180 2026-01-22

Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction

University of Alabama at Birmingham

Phase 1 Completed
20 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡